Aditxt
Pre-clinical stage, life sciences company with a mission to prolong life and enhance life quality of transplanted patients.
Launch date
Employees
Market cap
AUD2.5m
Enterprise valuation
AUD15m (Public information from Sep 2024)
Share price
$0.398 ADTX
Loma Linda California (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | <1m | <1m | <1m | 1.0m | 1.2m |
| % growth | - | - | - | 789 % | (31 %) | 55 % | 20 % |
| EBITDA | (5.9m) | (8.9m) | (27.0m) | (24.3m) | (25.5m) | - | - |
| % EBITDA margin | - | - | (25664 %) | (2601 %) | (3954 %) | - | - |
| Profit | (5.8m) | (9.1m) | (46.4m) | (27.6m) | (32.4m) | - | - |
| % profit margin | - | - | (44149 %) | (2961 %) | (5019 %) | - | - |
| EV / revenue | - | - | 192.0x | 6.0x | 40.9x | 6.8x | - |
| EV / EBITDA | - | -1.9x | -0.8x | -0.2x | -1.0x | - | - |
| R&D budget | <1m | <1m | 5.0m | 7.3m | 7.1m | - | - |
| R&D % of revenue | - | - | 4801 % | 778 % | 1096 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $11.0m | IPO | |
| N/A | $5.0m | Post IPO Equity | |
| N/A | $11.0m | Post IPO Equity | |
* | N/A | $20.0m | Post IPO Equity |
* | N/A | N/A | Private Placement VC |
* | N/A | $1.9m | Post IPO Equity |
* | N/A | $10.0m | Private Placement VC |
* | N/A | $6.0m | Private Placement VC |
* | N/A | $4.2m | Post IPO Convertible |
* | N/A | $1.2m | Post IPO Equity |
| Total Funding | AUD24.7m | ||
Related Content
Recent News about Aditxt
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Aditxt
Edit
ACQUISITION by Aditxt Apr 2024
ACQUISITION by Aditxt Dec 2021
ACQUISITION by Aditxt Dec 2023
ACQUISITION by Aditxt Oct 2021